| PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June |
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. |
globenewswire.com |
2025-04-29 20:03:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops |
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada. |
globenewswire.com |
2025-04-24 20:03:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript |
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Reza Zadno - President & Chief Executive Officer Sham Shiblaq - Executive Vice President & Chief Commercial Officer Kevin Waters - Executive Vice President & Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Securities Patrick Wood - Morgan Stanley Richard Newitter - Truist Brandon Vazquez - William Blair Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Mike Kratky - Leerink Partners Nathan Treybeck - Wells Fargo Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Operator Good morning and welcome to PROCEPT BioRobotics First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-04-24 18:37:36 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates |
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2025-04-24 13:20:45 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance |
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-04-24 11:00:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas |
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot. |
globenewswire.com |
2025-04-10 20:03:00 |
Czytaj oryginał (ang.) |
| WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation |
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomized, multicenter trial |
globenewswire.com |
2025-03-24 10:00:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada |
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. |
globenewswire.com |
2025-03-14 10:00:00 |
Czytaj oryginał (ang.) |
| Procept BioRobotics: Strong Growth, But Profitability Seems Far Away |
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA's clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal. |
seekingalpha.com |
2025-03-11 06:42:40 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript |
PROCEPT BioRobotics Corporation (PRCT) Q4 2024 Earnings Call Transcript |
seekingalpha.com |
2025-02-26 02:42:13 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates |
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-02-25 20:25:20 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results |
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the fourth quarter and year ended December 31, 2024. |
globenewswire.com |
2025-02-25 18:02:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference |
SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2024 after market close on Tuesday, February 25, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. |
globenewswire.com |
2025-02-07 10:00:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know |
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-01-16 15:00:30 |
Czytaj oryginał (ang.) |
| Procept BioRobotics resumed with an Overweight at Wells Fargo |
Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported by a new product cycle, the analyst tells investors in a research note. Procept is comfortable with 2025 consensus estimates, Wells says, adding that the firm is receiving "generally positive" physician feedback on Hydros. |
https://thefly.com |
2024-12-03 07:46:40 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 |
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 36th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Wednesday, December 4 at 8:30 a.m. Eastern Time. |
globenewswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| Procept BioRobotics: Continued Growth Runway Ahead |
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage. |
seekingalpha.com |
2024-11-26 07:10:32 |
Czytaj oryginał (ang.) |
| Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice |
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-11-07 15:00:42 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock |
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-10-29 22:43:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy |
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-10-29 15:01:15 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock |
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-10-28 18:19:00 |
Czytaj oryginał (ang.) |
| Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential |
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings. |
benzinga.com |
2024-10-28 16:17:31 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript |
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaway - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics Third Quarter 2024 Earnings Conference Call. At this time all participants' are in a listen-only mode. |
seekingalpha.com |
2024-10-28 12:32:08 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates |
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago. |
zacks.com |
2024-10-28 11:11:11 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance |
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024. |
globenewswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| Down -15.71% in 4 Weeks, Here's Why PROCEPT BioRobotics (PRCT) Looks Ripe for a Turnaround |
PROCEPT BioRobotics (PRCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-10-25 14:35:28 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
PROCEPT BioRobotics (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-21 15:05:31 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024 |
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2024 before market open on Monday, October 28, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. |
globenewswire.com |
2024-10-09 20:04:00 |
Czytaj oryginał (ang.) |
| PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer |
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients. |
zacks.com |
2024-10-08 17:45:22 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer |
A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer |
globenewswire.com |
2024-10-07 20:04:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024 |
SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time. |
globenewswire.com |
2024-08-28 20:03:00 |
Czytaj oryginał (ang.) |
| Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval |
The FDA's approval of Procept's Hrydos system is a meaningful catalyst to the investment debate. Investors have added ~$5/share in market value since the announcement. PRCT's Q2 '24 numbers were equally as strong and exhibited an extensive runway of growth ahead in my view. |
seekingalpha.com |
2024-08-27 12:30:00 |
Czytaj oryginał (ang.) |
| PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance |
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment. |
zacks.com |
2024-08-22 18:06:58 |
Czytaj oryginał (ang.) |
| PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS |
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning. |
zacks.com |
2024-08-22 14:16:11 |
Czytaj oryginał (ang.) |